STOCK TITAN
  1. Home
  2. Sec-filings
  3. DTIL
  4. [Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity

Precision Bio (DTIL) CRO sells 10,200 shares to cover RSU taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Precision BioSciences Chief Research Officer J. Jefferson Smith reported RSU vesting and a related tax sale. On January 20, 2026, RSUs covering 2,500, 10,447, and 16,219 shares vested, each RSU representing one share of common stock. On January 21, 2026, Smith sold 10,200 shares of common stock at $4.03 per share under a pre-arranged Rule 10b5‑1 plan as a sell‑to‑cover transaction for tax withholding tied to the RSU vesting.

Following these transactions, Smith directly owned 110,184 shares of Precision BioSciences common stock and held an additional 7,931 shares indirectly through a charitable remainder unitrust. RSU holdings after the transactions included 10,447 and 16,219 units that remain subject to their vesting schedules.

Positive

  • None.

Negative

  • None.
Insider SMITH J. JEFFERSON
Role Chief Research Officer
Sold 10,200 shs ($41K)
Approx. gross sale proceeds $41K
Approx. exercise cost $0.00
Type Security Shares Price Value
Exercise Common Stock 16,219 $0.00 $0.00
Sale Common Stock 10,200 $4.03 $41K
Exercise Restricted Stock Units 2,500 $0.00 $0.00
Exercise Restricted Stock Units 10,447 $0.00 $0.00
Exercise Restricted Stock Units 16,219 $0.00 $0.00
Exercise Common Stock 2,500 $0.00 $0.00
Exercise Common Stock 10,447 $0.00 $0.00
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Units — 26,666 shares (Direct); Common Stock — 110,184 shares (Direct); Common Stock — 7,931 shares (Indirect, By Charitable Remainder Unitrust)
Footnotes (7)
  1. F1. Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.
  2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
  3. F3. Includes 3,413 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a weighted average price per share of $5.74
  4. F4. The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
  5. F5. On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
  6. F6. On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
  7. F7. On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

FAQ

What insider activity did DTILs Chief Research Officer report on this Form 4?
The Form 4 shows J. Jefferson Smith, Chief Research Officer of Precision BioSciences (DTIL), had several RSU grants vest on January 20, 2026 and sold shares on January 21, 2026 to cover tax obligations related to those vestings.

How many Precision BioSciences shares did the CRO sell and at what price?
On January 21, 2026, the Chief Research Officer sold 10,200 shares of Precision BioSciences common stock at a price of $4.03 per share in a transaction designated as code S.

Were the DTIL insider share sales discretionary or part of a plan?
The sales were made under a Rule 10b5-1 trading plan adopted on April 25, 2024. The filing states the transaction was a sell-to-cover, with shares sold only to satisfy required tax withholding and related fees from RSU vesting.

How many Precision BioSciences shares does the CRO own after these transactions?
After the reported transactions, the Chief Research Officer directly owned 110,184 shares of Precision BioSciences common stock and indirectly held 7,931 shares through a charitable remainder unitrust.

What RSU grants for DTIL stock are described in the filing?
The filing describes RSU grants dated January 20, 2023, April 18, 2024, and August 22, 2024, each vesting in three substantially equal annual installments beginning on either January 20, 2024 or January 20, 2025, subject to continued service with the company.

How many Precision BioSciences RSUs remain outstanding for the CRO after the Form 4 events?
Following the vesting and conversions reported, the Chief Research Officer held 10,447 and 16,219 restricted stock units of Precision BioSciences, each representing a contingent right to receive one share of common stock, subject to their vesting schedules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SMITH J. JEFFERSON
(Last) (First) (Middle)
C/O PRECISION BIOSCIENCES, INC.
302 E. PETTIGREW STREET, SUITE A-100
(Street)
DURHAM NC 27701
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Research Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/20/2026 M 2,500(1) A (2) 93,718(3) D
Common Stock 01/20/2026 M 10,447(1) A (2) 104,165 D
Common Stock 01/21/2026 M 16,219(1) A (2) 120,384 D
Common Stock 01/21/2026 S(4) 10,200 D $4.03 110,184 D
Common Stock 7,931 I By Charitable Remainder Unitrust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 01/20/2026 M 2,500 (5) (5) Common Stock 2,500 $0 0 D
Restricted Stock Units (2) 01/20/2026 M 10,447 (6) (6) Common Stock 10,447 $0 10,447 D
Restricted Stock Units (2) 01/20/2026 M 16,219 (7) (7) Common Stock 16,219 $0 16,219 D
Explanation of Responses:
1. Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.
2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
3. Includes 3,413 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan at a weighted average price per share of $5.74
4. The sales were effected pursuant to a Rule 10b5-1 plan adopted on April 25, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
5. On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
6. On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
7. On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Remarks:
/s/ Dario Scimeca Attorney-in-fact for Jeff Smith 01/22/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR